AC Immune’s Promising Pipeline and Strong Financial Position Justify Buy Rating

Leerink Partners analyst Marc Goodman maintained a Buy rating on AC Immune SA (ACIU – Research Report) on May 2 and set a price target of $9.00.

Marc Goodman has given his Buy rating due to a combination of factors including AC Immune’s promising pipeline developments and strong financial position. The company has reported encouraging interim results from its Phase 2 study of the anti-alpha-synuclein immunotherapy, ACI-7104, which showed significantly higher antibody titers compared to placebo. Additionally, the upcoming data from various trials, including the ABATE Phase 2 trial for ACI-24 and the Phase 1 study of the TDP-43-PET tracer, are anticipated to provide further insights into the efficacy of their treatments.
AC Immune’s financial health is also a contributing factor to the Buy rating. The company ended the first quarter of 2025 with CHF 146 million in cash, which is expected to fund operations into the first quarter of 2027. Moreover, the progress in their Morphomer Tau and Morphomer alpha-syn programs, as well as the expected IND filing for ACI-19764, highlight the company’s robust and diversified pipeline. These elements, combined with strong partnerships, underpin the positive outlook and the reiterated price target of $9.

In another report released on May 4, BTIG also maintained a Buy rating on the stock with a $8.00 price target.